The caspase-1 inhibitor VX-765 has shown anti-tumor effects through the inhibition of pyroptosis and reduction in IL-1β secretion in non-small cell lung cancer (NSCLC) models [192]. This evidence concerns the gene CASP1 and non-small cell lung carcinoma.